This page contains exclusive content for the member of the following sections: TTS, CTS, IPITA, ISODP, IXA, ITA, TID, IHCTAS, IPTA, SPLIT, ISUTX. Log in to view.
2024 - TTS Education Webinar Series
10727.10 - Cancer in Solid Organ Transplantation
Presenter: Eric Au, Abhijat Kitchlu, Naoka Murakami, , , Authors: Eric Au, Abhijat Kitchlu, Naoka Murakami, Georgina Irish
Outline
De novo malignancies post solid organ transplantation have always been a key concern of long-term immunosuppression. This webinar will describe the evidence and important updates on pre- and post-transplant screening and management consideration for chemotherapy in transplant recipients.
Learning Objectives
Pre-transplant screening for cancer in prospective transplant recipients
Post-transplant screening for cancer in transplant recipients
Understanding chemotherapy risks in transplant recipients
Nephrologist,
Australian and New Zealand Dialysis and Transplant Registry
Adelaide, Australia
Dr Georgina L. Irish is an Australian Transplant Nephrologist currently working at The Royal Adelaide Hospital. She is the Director of Projects and Analytics for the Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry. She is the Medical Director of Transplant Australia.
Nephrologist, Alfred Hospital, Clinical Epidemiology Fellow, ANZDATA
Melbourne, Australia
Eric is a nephrologist at the Alfred Hospital in Melbourne and recently joined ANZDATA as the ANZSN/ANZDATA clinical epidemiology fellow. He has undertaken training in epidemiology and biostatistics at the University of Sydney and completed a PhD project on the epidemiology of cancer after kidney transplantation in 2022.
Staff Nephrologist, Assistant Professor
University Health Network
Toronto, Canada
Dr. Abhijat Kitchlu, MD, MSc is a Staff Nephrologist and Director of the Onco-nephrology Program at the University Health Network in Toronto. He is an Assistant Professor in the Department of Medicine at the University of Toronto. His research and clinical interest include onco-nephrology (co-existing cancer and kidney disease), with specific focus on toxicities of cancer therapies and cancer treatment options in the setting of chronic kidney disease. He also has interest and expertise in the use of population-level healthcare administrative data for clinical research. He currently serves on the Board of Directors of the American Society of Onco-Nephrology (ASON) and is Co-chair of the ASON Position Statement Committee.
Assistant Professor
Brigham and Women’s Hospital, Harvard Medical School
Boston, MA, USA
Naoka Murakami, MD PhD, is Assistant Professor of Medicine at Harvard Medical School and a transplant nephrologist at Brigham and Women's Hospital. She received MD-PhD degree from University of Tokyo, Japan, and completed Nephrology fellowship in the combined program at Brigham and Women's Hospital and Massachusetts General Hospital. Her primary research interest is allograft tolerance and T cell immunobiology. Her research project has been supported by NIH and American Society of Nephrology. Her clinical focus is on the care for kidney transplant recipients with cancer (Transplant Onconephrology), in collaboration with Dana-Farber Cancer Institute.
Important
Disclaimer
By viewing the material on this site you understand and
accept that:
The opinions and statements expressed on this site reflect the
views of the author or authors and do not necessarily reflect those of
The Transplantation Society and/or its Sections.
The hosting of material on The Transplantation Society site does
not signify endorsement of this material by The Transplantation Society
and/or its Sections.
The material is solely for educational purposes for qualified
health care professionals.
The Transplantation Society and/or its Sections are not liable for
any decision made or action taken based on the information contained in
the material on this site.
The information cannot be used as a substitute for professional
care.
The information does not represent a standard of care.
No physician-patient relationship is being established.